- Home
- IBIO vs COSM Comparison
IBIO vs COSM Comparison
Compare IBIO & COSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IBIO | COSM |
|---|---|---|
| Founded | 2008 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Other Pharmaceuticals |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.4M | 15.4M |
| IPO Year | N/A | 2013 |
Fundamental Metrics
Financial Performance| Metric | IBIO | COSM |
|---|---|---|
| Price | $1.95 | $0.41 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $4.50 | N/A |
| AVG Volume (30 Days) | ★ 13.0M | 616.4K |
| Earning Date | 11-12-2025 | 11-17-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $500,000.00 | ★ $59,792,819.00 |
| Revenue This Year | N/A | $28.14 |
| Revenue Next Year | $11.11 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 185.71 | 6.69 |
| 52 Week Low | $0.56 | $0.28 |
| 52 Week High | $6.89 | $1.32 |
Technical Indicators
Market Signals| Indicator | IBIO | COSM |
|---|---|---|
| Relative Strength Index (RSI) | 58.34 | 21.01 |
| Support Level | $0.98 | $0.44 |
| Resistance Level | $3.82 | $0.46 |
| Average True Range (ATR) | 0.38 | 0.05 |
| MACD | 0.10 | -0.00 |
| Stochastic Oscillator | 34.15 | 2.14 |
Price Performance
Historical ComparisonAbout IBIO iBio Inc.
iBio Inc is a preclinical stage biotechnology company that leverages the power of Artificial Intelligence (AI) for the development of precision antibodies. CDMO. Its technology stack is designed to minimize downstream development risks by employing AI-guided epitope-steering and monoclonal antibody (mAb) optimization.
About COSM Cosmos Health Inc.
Cosmos Health Inc is engaged in the nutraceuticals sector through its own proprietary lines of products 'Sky Premium Life' and 'Mediterranation'. Additionally, the firm is operating in the pharmaceutical sector through the provision of a broad line of branded over-the-counter drugs and branded and generic medicines. The company's focus will be on Branded Pharmaceuticals, Over-the-Counter medicines, and Generic Pharmaceuticals. It provides its products to wholesale drug distributors, wholesalers, and retail healthcare providers. The company's segment are Wholesale, Pharma Manufacturing, Nutraceuticals & Pharmaceuticals and Other. It derives maximum revenue from Wholesale Segment.